Cytosorbents Corp 4
4 · Cytosorbents Corp · Filed Apr 10, 2015
Insider Transaction Report
Form 4
BARTLETT ROBERT HAWES
Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2015-04-08+20,000→ 20,000 totalExercise: $8.07Exp: 2020-04-08→ Common Stock (20,000 underlying) - Award
Common Stock
2015-04-08+30,000→ 30,000 total
Footnotes (2)
- [F1]These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.
- [F2]Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, 45% of which vest upon achieving 2015 budgeted revenues and not exceeding budgeted operating expenses; 30% of which vest upon achievement of multiple clinical trial objectives in calendar year 2015, as determined in the discretion of the Board of Directors; 15% of which vests upon demonstration of reasonable progress in the U.S. regulatory approval of one of CytoSorbents Corporation's products, as determined in the discretion of the Board of Directors; and 10% of which vests upon achievement of one or more new major strategic partnerships, as determined in the discretion of the Board of Directors.